secwatch.observer — SEC 8-K summary
======================================

Issuer:     HOOKIPA Pharma Inc. (HOOK)
CIK:        0001760542
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001558370-23-018410
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HOOKIPA reports Q3 2023 net loss of $19.1M; HB-200 shows 42% ORR in HPV16+ HNSCC
--------------------------------------------------------------------------------

- Revenue of $6.9M, up from $2.2M YoY, mainly from Gilead and Roche collaboration recognition.
- Net loss of $19.1M vs $18.3M YoY; R&D expenses increased to $24.6M from $18.3M.
- Cash and equivalents $108.1M as of Sep 30, 2023, down from $113.4M at Dec 31, 2022.
- HB-200 + pembro achieved 42% ORR in 19 evaluable CPI-naïve patients, doubling historical 19% for pembro alone.
- Anticipated milestones: Phase 2 HB-200 data H1 2024, randomized trial mid-2024; IND filings for HB-700 (H1 2024) and HB-500 (Q4 2023).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1760542/000155837023018410/0001558370-23-018410-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1760542/000155837023018410/hook-20231109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-018410

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer